Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus FEMINONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus FEMINONE.
ESTRADIOL CYPIONATE vs FEMINONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
FEMINONE (progesterone) is a steroid hormone that binds to the progesterone receptor, modulating gene expression in target tissues. It transforms the endometrium from proliferative to secretory phase, reduces endometrial hyperplasia risk, and suppresses gonadotropin release via negative feedback.
1-5 mg intramuscularly every 3-4 weeks.
0.625 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Terminal elimination half-life is approximately 7-8 hours (range 5-12 h); clinical significance: steady-state reaches after ~2-3 days, necessitates daily dosing for contraceptive efficacy.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Feminone (norethindrone) is primarily excreted in urine (approximately 70-80% as metabolites, with <5% as unchanged drug) and feces (20-30%).
Category D/X
Category C
Estrogen
Estrogen